LXG6403 is a bi-thiazole potent inhibitor of LOX cellular activity with an IC50 of 1.3 μM. It exhibits anti-cancer activity by remodeling the extracellular matrix, enhancing chemotherapy penetration, inducing ROS generation, and promoting DNA damage-mediated cell death to overcome chemotherapy resistance in triple-negative breast cancer.

LXG6403 is a bi-thiazole potent inhibitor of LOX cellular activity with an IC50 of 1.3 μM. It exhibits anti-cancer activity by remodeling the extracellular matrix, enhancing chemotherapy penetration, inducing ROS generation, and promoting DNA damage-mediated cell death to overcome chemotherapy resistance in triple-negative breast cancer.

LXG6403 is a bi-thiazole potent inhibitor of LOX cellular activity with an IC50 of 1.3 μM. It exhibits anti-cancer activity by remodeling the extracellular matrix, enhancing chemotherapy penetration, inducing ROS generation, and promoting DNA damage-mediated cell death to overcome chemotherapy resistance in triple-negative breast cancer.

Asandeutertinib (Osimertinib-d3, AZD-9291-d3) is an orally administered, ATP-competitive, irreversible, deuterated third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) and a deuterium-stabilized derivative of osimertinib, with the potential to treat advanced EGFR-mutated NSCLC.

Asandeutertinib (Osimertinib-d3, AZD-9291-d3) is an orally administered, ATP-competitive, irreversible, deuterated third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) and a deuterium-stabilized derivative of osimertinib, with the potential to treat advanced EGFR-mutated NSCLC.

Asandeutertinib (Osimertinib-d3, AZD-9291-d3) is an orally administered, ATP-competitive, irreversible, deuterated third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) and a deuterium-stabilized derivative of osimertinib, with the potential to treat advanced EGFR-mutated NSCLC.

ES9-17 is a potent, selective and reversible inhibitor of Clathrin-mediated endocytosis (CME). It bind to the N-terminal domain (nTD) of the clathrin heavy chain (CHC), inhibiting the uptake of FM4-64 and of several CME cargos in Arabidopsis.

Asandeutertinib (Osimertinib-d3, AZD-9291-d3) is an orally administered, ATP-competitive, irreversible, deuterated third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) and a deuterium-stabilized derivative of osimertinib, with the potential to treat advanced EGFR-mutated NSCLC.

ES9-17 is a potent, selective and reversible inhibitor of Clathrin-mediated endocytosis (CME). It bind to the N-terminal domain (nTD) of the clathrin heavy chain (CHC), inhibiting the uptake of FM4-64 and of several CME cargos in Arabidopsis.

ES9-17 is a potent, selective and reversible inhibitor of Clathrin-mediated endocytosis (CME). It bind to the N-terminal domain (nTD) of the clathrin heavy chain (CHC), inhibiting the uptake of FM4-64 and of several CME cargos in Arabidopsis.